Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.

Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD.

Arthritis Rheum. 2013 Feb;65(2):464-71. doi: 10.1002/art.37759.

2.

[Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review].

Pons I, Espinosa G, Cervera R.

Med Clin (Barc). 2015 Feb 2;144(3):97-104. doi: 10.1016/j.medcli.2014.01.034. Spanish.

PMID:
24698717
4.
6.

Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.

Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM.

Arthritis Rheum. 2004 Aug;50(8):2569-79.

7.

Rituximab induces resolution of recurrent diffuse alveolar hemorrhage in a patient with primary antiphospholipid antibody syndrome.

Scheiman Elazary A, Klahr PP, Hershko AY, Dranitzki Z, Rubinow A, Naparstek Y.

Lupus. 2012 Apr;21(4):438-40. doi: 10.1177/0961203311422713.

PMID:
21993385
8.

Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study.

Del Ross T, Ruffatti A, Visentin MS, Tonello M, Calligaro A, Favaro M, Hoxha A, Punzi L.

J Rheumatol. 2013 Apr;40(4):425-9. doi: 10.3899/jrheum.120576.

PMID:
23418380
9.

Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.

Tarr T, Lakos G, Bhattoa HP, Soltesz P, Shoenfeld Y, Szegedi G, Kiss E.

Clin Rev Allergy Immunol. 2007 Apr;32(2):131-7.

PMID:
17916982
11.

The geoepidemiology of the antiphospholipid antibody syndrome.

Biggioggero M, Meroni PL.

Autoimmun Rev. 2010 Mar;9(5):A299-304. doi: 10.1016/j.autrev.2009.11.013. Review.

PMID:
19932199
12.

What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?

Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A.

Semin Thromb Hemost. 2012 Jun;38(4):322-7. doi: 10.1055/s-0032-1304719. Review.

PMID:
22399307
13.
14.

The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.

Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR.

J Rheumatol. 2001 Dec;28(12):2637-43.

PMID:
11764209
15.
16.

Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels.

Mekinian A, Loire-Berson P, Nicaise-Roland P, Lachassinne E, Stirnemann J, Boffa MC, Chollet-Martin S, Carbillon L, Fain O.

J Reprod Immunol. 2012 Jun;94(2):222-6. doi: 10.1016/j.jri.2012.02.004.

PMID:
22386067
17.

Lack of association between antiphospholipid antibodies and thrombocytopenia in patients with Wegener's granulomatosis.

Meyer MF, Schnabel A, Schatz H, Gross WL.

Semin Arthritis Rheum. 2001 Aug;31(1):4-11.

PMID:
11503134
18.

Non-criteria manifestations of antiphospholipid syndrome.

Erkan D, Lockshin MD.

Lupus. 2010 Apr;19(4):424-7. doi: 10.1177/0961203309360545.

PMID:
20353981
19.

Catastrophic antiphospholipid syndrome: a case series.

Shiber S, Yair M.

Isr Med Assoc J. 2013 Sep;15(9):481-4.

20.

Anti-beta 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome.

Teixidó M, Font J, Reverter JC, Cervera R, Tàssies D, Ingelmo M, Escolar G, Ordinas A.

Br J Rheumatol. 1997 Jan;36(1):113-6.

PMID:
9117149
Items per page

Supplemental Content

Support Center